Deals Shaping the Medical Industry (09/1996)
Summarizing the deals in the medical industry.
You may also be interested in...
SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.
Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.